Dantoing, E.; Piton, N.; Salaün, M.; Thiberville, L.; Guisier, F.
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. Int. J. Mol. Sci. 2021, 22, 6288.
https://doi.org/10.3390/ijms22126288
AMA Style
Dantoing E, Piton N, Salaün M, Thiberville L, Guisier F.
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. International Journal of Molecular Sciences. 2021; 22(12):6288.
https://doi.org/10.3390/ijms22126288
Chicago/Turabian Style
Dantoing, Edouard, Nicolas Piton, Mathieu Salaün, Luc Thiberville, and Florian Guisier.
2021. "Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations" International Journal of Molecular Sciences 22, no. 12: 6288.
https://doi.org/10.3390/ijms22126288
APA Style
Dantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F.
(2021). Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. International Journal of Molecular Sciences, 22(12), 6288.
https://doi.org/10.3390/ijms22126288